March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Vegf-pretreated Islets Transplant In Prevention Of Diabetic Retinopathy In Sd Rats
Author Affiliations & Notes
  • Chunzhi Dou
    Biology, Georgia Unviversity System/Georgia Gwinnett College, Lawrenceville, Georgia
  • Xuewen Zhang
    Surgery,
    Norman Bethune Medical College, Jilin University, Changchun, China
  • Shuyan Gu
    Ophthalmology,
    Norman Bethune Medical College, Jilin University, Changchun, China
  • Tiehua DOU
    Endocrinology, Dehui County Hospital, Dehui, China
  • Stanley Wu
    Pharmacology, Indiana University, Indainapolis, Indiana
  • Footnotes
    Commercial Relationships  Chunzhi Dou, None; Xuewen Zhang, None; Shuyan Gu, None; Tiehua Dou, None; Stanley Wu, None
  • Footnotes
    Support  Mengxianmin Foundation
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5433. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chunzhi Dou, Xuewen Zhang, Shuyan Gu, Tiehua DOU, Stanley Wu; Vegf-pretreated Islets Transplant In Prevention Of Diabetic Retinopathy In Sd Rats. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5433.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study pancreatic islets transplantation in the context of VEGF- pretreatment to prevent diabetic retinopathy in SD rats.

Methods: : Methods: The current research project was conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. In this study, diabetic rat model was made by intraperitoneal injection of Streptozotocin (STZ). One week after the injection, islets from donor rats were isolated with collagenase and transplanted under the kidney capsule with different treatment. Receiver rats were divided into three groups depending on the islets treatment. Group V received VEGF pre-cultured islets transplant; group M received islets transplant through media-pretreated islets; and group C received islets without pre-culture. Blood glucose and body weight were monitored daily after the transplant. At the end of study, the transplanted islets were retrieved for immunohistochemistry study; and eyes were enucleated for diabetic retinopathy evaluation.

Results: : Results: Blood glucose was very well controlled through the whole study course with stable body weight in group V rats. Animals in group M showed short period of normal blood glucose and body weight maintenance; while the group C animals only had initial two days of normal blood glucose and experienced body weight loss through the whole time course of the study. In terms of diabetic retinopathy, 13% of animals in group M developed mild NPDR, 54% with moderate NPDR, 17% with severe NPDR and PDR. In group C receivers, 8% developed mild NPDR, 58% developed moderate NPDR, 8% developed severe NPDR, and 25% developed PDR. In group V, however, only one animal (4%) developed mild NPDR and no moderate or severe NPDR or PDR development during the whole study period.

Conclusions: : Conclusions: From this study, we concluded that rats received VEGF-pretreated islets could maintain normal blood glucose level, normal body weight and no serious diabetic retinopathy. It indicated that the VEGF promoted blood vessels regeneration in the islets grafts but did not cause worsening diabetic retinopathy due to its indirect euglycemia effect by maintaining islets grafts re-vascularization. This result supported the previous study that the VEGF worsened diabetic retinopathy through neovascularization was secondary to the long-term effect of hyperglycemia in diabetes patients.

Keywords: diabetic retinopathy • microscopy: light/fluorescence/immunohistochemistry • imaging/image analysis: non-clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×